BioDelivery Sciences receives FDA approval for Bunavail buccal film for the maintenance treatment of opioid dependence


Friday, 6 Jun 2014 05:20pm EDT 

BioDelivery Sciences International Inc:Receives approval of the New Drug Application (NDA) for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration.BUNAVAIL is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.Expects to launch BUNAVAIL late in the third quarter of 2014. 

Company Quote

11.97
-0.68 -5.38%
26 Dec 2014